IRIS
STORTI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.832
EU - Europa 2.320
AS - Asia 1.556
AF - Africa 47
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 3
OC - Oceania 2
Totale 6.769
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.783
CN - Cina 943
SE - Svezia 531
IE - Irlanda 499
SG - Singapore 407
FI - Finlandia 378
IT - Italia 304
DE - Germania 250
TR - Turchia 154
UA - Ucraina 78
FR - Francia 62
AT - Austria 53
CA - Canada 48
CI - Costa d'Avorio 41
RO - Romania 34
CZ - Repubblica Ceca 32
BE - Belgio 31
GB - Regno Unito 28
IN - India 27
NL - Olanda 11
EU - Europa 9
IR - Iran 5
LT - Lituania 5
BG - Bulgaria 4
RU - Federazione Russa 4
AE - Emirati Arabi Uniti 3
HK - Hong Kong 3
KZ - Kazakistan 3
AU - Australia 2
CH - Svizzera 2
CM - Camerun 2
ES - Italia 2
IL - Israele 2
LU - Lussemburgo 2
MD - Moldavia 2
NG - Nigeria 2
PH - Filippine 2
PT - Portogallo 2
SC - Seychelles 2
SM - San Marino 2
AR - Argentina 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BZ - Belize 1
CO - Colombia 1
DK - Danimarca 1
HR - Croazia 1
JP - Giappone 1
KG - Kirghizistan 1
KH - Cambogia 1
PK - Pakistan 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 6.769
Salva come PNG Salva come JPEG
Città #
Chandler 538
Dublin 499
Singapore 333
Santa Clara 317
Beijing 211
Ashburn 178
Jacksonville 157
Parma 154
Ann Arbor 145
Izmir 138
Nanjing 133
Boardman 126
Dearborn 125
Shanghai 117
Princeton 90
New York 73
San Mateo 62
Munich 61
Kunming 58
Vienna 53
Shenyang 52
Wilmington 50
Marseille 43
Toronto 43
Abidjan 41
Helsinki 40
Nanchang 38
Hebei 34
Düsseldorf 32
Jiaxing 32
Brussels 31
Jinan 30
Tianjin 30
Bremen 29
Brno 27
Hefei 25
Los Angeles 24
Des Moines 23
Focsani 22
Changsha 20
Seattle 16
Hangzhou 15
Kocaeli 15
Pune 14
Woodbridge 14
Norwalk 13
Redmond 12
Zhengzhou 12
Milan 11
Bologna 10
Chengdu 9
Guangzhou 9
Jesi 9
Taizhou 9
Frankfurt am Main 8
Fuzhou 8
Houston 8
London 8
Dallas 7
Rome 7
Fairfield 6
Mestre 6
Palermo 6
Rockville 6
Chongqing 5
Modena 5
Ningbo 5
Wuhan 5
Borås 4
Cambridge 4
Chicago 4
Fremont 4
Haikou 4
Ottawa 4
Rho 4
Savignano sul Rubicone 4
Sofia 4
Timisoara 4
Washington 4
Ahmedabad 3
Catania 3
Cesena 3
Dubai 3
Huizen 3
Leawood 3
Nürnberg 3
Reggio Emilia 3
St Louis 3
Taiyuan 3
Almaty 2
Arcevia 2
Baotou 2
Boston 2
Central 2
Chisinau 2
Cornaredo 2
Edinburgh 2
Forest City 2
Geislingen an der Steige 2
Grafing 2
Totale 4.588
Salva come PNG Salva come JPEG
Nome #
Are the Myeloma bone microevironment cells tumoral or not? 114
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 114
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 111
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 106
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 105
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 105
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 104
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 103
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 101
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 101
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 99
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 98
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 97
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 95
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 94
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 94
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 92
Novel targets for the treatment of relapsing multiple myeloma 91
Possible targets to treat myeloma-related osteoclastogenesis 88
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 87
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 87
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 87
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 86
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 84
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 84
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 84
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 84
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 84
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 83
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 81
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 81
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 80
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 80
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 79
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 79
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 79
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 79
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 78
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 78
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 77
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 77
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 76
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 76
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 76
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 75
Comet assay and prediction of clinical outcome after DNA-damaging drugs treatment 75
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 75
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 74
Angiogenesis and multiple myeloma 73
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 72
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 72
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 71
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 70
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 70
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 70
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 70
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome 69
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 69
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 68
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 67
ASSESSMENT OF THE INTERLABORATORY VARIABILITY AND ROBUSTNESS OF JAK2V617F MUTATION ASSAYS: A STANDARDIZATION STUDY INVOLVING A CONSORTIUM OF 19 ITALIAN LABORATORIES 67
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 66
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 65
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 65
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 65
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 64
Role of Galectins in Multiple Myeloma. 61
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 60
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 58
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 58
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 58
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 57
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 57
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 57
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA 56
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 55
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 54
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 52
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 52
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 52
Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts 52
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 52
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 50
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 50
The impact of CD56 expression in smoldering myeloma patients on early progression 49
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 49
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 47
Is there a way to predict the clinical outcome of DNA strand breaks generating drugs? The case of calicheamicin 47
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 46
Detection of DNA strand breaks as individual predictive response to Gemtuzumab Ozogamicin in acute myeloid leukaemia 40
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 39
The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged 37
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 34
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 33
CD38 expression by plasma cells in extramedullary multiple myeloma 27
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 26
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 19
Totale 6.954
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.118
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.118
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020499 0 0 0 0 0 100 105 24 70 113 39 48
2020/2021464 33 37 20 10 76 10 26 23 110 32 50 37
2021/2022491 14 9 15 42 13 10 67 55 19 42 39 166
2022/20232.037 213 229 152 148 168 227 66 137 599 25 56 17
2023/2024776 30 71 14 19 55 215 77 34 21 46 51 143
2024/20251.063 56 108 133 234 269 263 0 0 0 0 0 0
Totale 6.954